In Brief: St. Jude Medical
This article was originally published in The Gray Sheet
St. Jude Medical: Firm's Passive Plus DX passive-fixation, steroid eluting pacing lead gains FDA approval, the company announces Feb. 5. The new lead further expands the St. Jude Cardiac Rhythm Management Division portfolio of pacing leads -- the Tendril DX active-fixation, steroid-eluting lead debuted last year...
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.